Mallinckrodt (MNK) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales increased 8.3% year-over-year to $514.3M, driven by Specialty Generics growth and partially offset by declines in certain Specialty Brands.

• Adjusted EBITDA for Q2 2024 grew 20.8% to $174.0M, reflecting strong execution and stabilization of the base business.

• Net loss for Q2 2024 was $43.3M, a 94.2% improvement from the prior year.

• Announced the sale of the Therakos business to CVC Capital Partners for $925M, with proceeds to reduce net debt by over 50%.

• Emerged from Chapter 11 bankruptcy in November 2023, adopting fresh-start accounting and restructuring its capital structure.

Financial highlights

• Q2 2024 net sales: $514.3M (+8.3% year-over-year); six-month net sales: $982.1M (+9.2%).

• Q2 2024 adjusted EBITDA: $174.0M (+20.8%); six-month adjusted EBITDA: $318.9M (+19.2%).

• Q2 2024 net loss: $43.3M, improved from $747.8M loss in Q2 2023; six-month net loss: $108.7M, down from $997.1M.

• Adjusted gross profit margin improved to 65.2% from 62.8% in Q2 2023; reported gross margin was 37.9%.

• Cash and cash equivalents at quarter end were $291.1M, up from $253.6M in Q1.

Outlook and guidance

• Full-year 2024 net sales guidance raised to $1.9B–$2.0B, a 5.4% increase at midpoint.

• Full-year adjusted EBITDA guidance raised to $585M–$615M, an 11.1% increase at midpoint.

• Acthar Gel net sales expected to grow in the low to mid-single digits in 2024.

• Therakos divestiture impact not included in updated guidance.

• Management continues to evaluate further divestitures to reduce debt and maximize shareholder value.